by Trevor Kearing – May 29, 2016
Globus Medical Inc (NYSE:GMED) has been given a consensus rating of “Hold” by the eleven research firms that are presently covering the firm. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $27.67. 
A number of analysts have commented on GMED shares. Leerink Swann reissued an “outperform” rating and set a $29.00 price objective (down from $32.00) on shares of Globus Medical in a report on Thursday, February 25th. Canaccord Genuity reissued a “buy” rating and set a $30.00 price objective on shares of Globus Medical in a report on Thursday, February 25th. William Blair reissued an “outperform” rating on shares of Globus Medical in a report on Wednesday, February 24th. Zacks Investment Research lowered Globus Medical from a “buy” rating to a “hold” rating in a report on Wednesday, April 27th. Finally, Oppenheimer reissued a “buy” rating and set a $29.00 price objective on shares of Globus Medical in a report on Wednesday, May 4th.